Pharmaceutical giant Pfizer’s CEO on Tuesday said that the company is “very close” to applying for an emergency use approval for its COVID-19 vaccine after gathering safety data to present to the US Food and Drug Administration (FDA), reported AFP.

“We are very close to submitting for an emergency use authorization,” Albert Bourla told medical news site Stat. “We will announce it as soon as we are doing it,” he added.

Also read: France aims to kick off vaccinations for novel coronavirus in January

Last week, Pfizer announced that primary results from a clinical trial showing the injections it had co-created with Germany’s BioNTech were more than 90% effective after the second dose.

The company had previously announced that it could apply for an Emergency Use Authorization at the FDA in the third week of November.

Also read: COVID-19 vaccine trials encouraging. Here’s who will get it first

On Monday, Moderna and the US National Institutes for Health announced similar preliminary results from their own trial, finding their vaccine was almost 95% effective.

Since companies that have been funded by the government have already been manufacturing their doses ahead of approval, Moncef Slaoui, chief of the US government’s Operation Warp Speed for vaccine and treatment development, says that there will be enough between Pfizer and Moderna to immunize 20 million Americans in December.